It has been generally recognized that human growth hormone (HGH) has the effect to facilitate growth in cases of pituitary dwarfism. As of April 1970, however, there are only 33 reported cases in the world in which HGH has been administered for more than two years (Soyka et al., 1970) . We have treated 14 cases of pituitary dwarfism with HGH, and observed initial increases in growth rate in all cases. In two of the cases the therapy became practically ineffective after several months, whereas in the other twelve it remained effective for more than one year. Some of these cases were previously reported (Shizume, 1968 (Shizume, 1969 . The present paper reports the results on five of the above-mentioned twelve cases in which HGH therapy has been continued for more than three years.
Method
In this study, height age was based on the average height and standard deviation for each age shown in 1967 School Health Statistics compiled by the Statistics Section of the Ministry of Education (age in these statistics is in terms of whole years as of April 1; for example, a group "ten years old" includes children ranging from exactly ten years of age to ten years and 364 days; in our data, the average height for the age of ten chronological years represents the calculated mean of the figures (or the ages of nine and ten shown in the Ministry of Education staistics), and bone age was estimated by comparing radiographs of the left hand and wrist with the standards of Greulich and Pyle (1950) . The HGH used had been extracted from acetone-fixed human pituitary glands by the Raben method (1962).
Results
Case 1 N. K., female (Fig. 1 Growth hormone secretion test (insulin hypoglycemia) From these data it was concluded that the secretion of ACTH, TSH, and ADH were normal and the secretion of GH was deficient whereas it was impossible to determine whether the secretion of GTH was deficient or not (since the patient might had been before adolescence). In January 1966, 2 mg of HGH started to be administered intramuscularly three times a week. During the first six months with this therapy the patient grew 5.4 cm, and in the subsequent six-month period 3.4 cm, 3.2 cm, 4.0 cm, 5.0 cm (meanwhile secondary sex characteristics developed), and 4.4 cm, respectively. In August 1969 (16 2/12 years old) his height was 158 cm (height age 14 4/12 years). Since the average height of normal males 16 2/12 years old is 163.5 cm and the Case 4 R. M., female (Fig. 4) At the time of initial diagnostic evaluation (in August, 1967) the patient was 7 2/12 years old, 98 cm high (height age, 3 3/12 years), and weighed 16 kg. Her bone age was 1 10/12 years. In the preceding eight months she had grown by only 1.5 cm. The endocrine function tests gave the following results:
Thyroid function tests: From these data this case was diagnosed as pituitary dwarfism due to GH and TSH deficiency. Since September, 1967, 0.05 g/day of desiccated thyroid was administered for two months, but during this two-month period the patient grew only 0.5 cm. Since November, 1967, 2 mg of HGH started to be administered intramuscularly three times per week. In the first six months with this therapy she grew by 7.5 cm, and in the subsequent two Figure 5 . Initial HGH administration for four months resulted in a height gain of 2.0 cm.(During this period, the patient was not receiving injections regularly). Later she refused to get injections of HGH due to the pain at the site of injection, and for one and a half years until January 1965 she was only taking desiccated thyroid orally. Meanwhile she grew by only 3.5 cm (at the rate of 1.2 cm per six months). HGH therapy was resumed in January, 1965, and for five months 2 mg of HGH was injected intramuscularly three times a week. In the first three months the patient grew 2.5 cm, but in the subsequent period of two months practically no gain in height was observed (conceivably because the patient was not receiving injections regularly). Beginning in June 1965, the dose was increased to 4 mg each time. A height gain of 0.8 cm per month was observed until the schedule of injection was interrupted by a summer vacation tour made by the patient. It was resumed in September, 1965, and since then 4-mg has been admin' istered intramuscularly three times a week, although the patient has often failed to receive injections, sometimes only once a week. Meanwhile, her height measured every six months has shown successive increases of 2.6 cm, 0.9 cm, 1.7 cm, 2.0 cm, 3.0 cm, 3.4 cm, 1.6 cm, 0.3 cm, and 0.5 cm. By the end of December, 1969 (chronologic age, 19 6/12 years), she was 145.3 cm high (height age, 12 1/12 years). Since the average height of females 18 6/12 years old is 154.5 cm and the standard deviation (a), 5.1 cm, our patient was now 1 cm above the level of -2u of average height, or 144.3 cm.
Her bone age was 7 10/12 years in January, 1963, but reached to 13 years by July, 1968, increasesing 5 4/12 years in 5 7/12 years. Roughly there was a bone age gain of one year per calendar year. Practically no increase was observed between July, 1968 and October, 1969, presumably because no secondary sex characteristics developed.
In January, 19700 (6 9/12 years after HGH therapy was started), the patient's blood was checked by radioimmunoassay for HGH antibodies, but the presence was not observed.
The data in these five cases are summarized in Table 1 . Although in Case 1, 2, 4, and 5, thyroid hormone was administered almost concurrently with the administration of HGH, the promotion of growth in these cases cannot be attributed to the direct effect of thyroid hormone because of the following reasons. In Case 1, administration of desiccated thyroid for about one year beginning at the age of 10 months had n growth promoting effect. In Case 3, at the period when HGH administration was only once a week, the patient failed to show any increase in height even though he was receiving desiccated thyroid. In Case 4, when only dessicated thyroid was administered for 2 months before the administration of HGH, no significant growth promotion was observed. In Case 5, when the patient was taking only desiccated thyroid, she grew by only 3.5 cm in one and a half years, which was a usual height increase in pituitary dwarfism. Therefore the growth promotion in these cases can be attributed mainly to the effect of HGH although it is conceivable that concurrent administration of thyroid hormone contributed to some extent to the effect of HGH. As seen from the table, patients treated wi th HGH early in their lives, such as Case 1 (N. K.) and Case 4 (R. M.), tend to show increase in height age by far exceeding their chronologic age increases. In Case 3 (T. N.), also height age has increased much faster than chronologic age, although, as previously noted, this growth may have been partly due to the secretion of androgen accompanying the development of secondary sex characteristics. In Case 2 and 5, there have Table 1 . Height age and bone age increases through HGH therapy been more increases in chronologic age than in height age, presumably because HGH has not been administered regularly. The bone age/height age progress ratio is 51/72=0.71 in Case 1,18/37=0.49 in Case 2 , 54/66= 0.82 in Case 3, 28/49=0.57 in Case 4, and 62/52=1.19 in Case 5. In other words , the progress of bone age has been slower than that of chronologic age in Case 1 through 4 . The situation is reversed in Case 5, probably because the patient has not regularly been receiving HGH injections, while thyroid hormone has been administered continuously .
The six-month height increases in each case are shown in Table 2 . In the first six months they all showed remarkable increases, averaging 5.9cm (Case 5 is not included as the patient was not receiving injections regulary). The average increase then declined gradually , to 4.2 cm in the second six-month period , 3.8 cm in the third, and 3.4cm in the fourth .
With respect to the dosage and frequency of injection, administration of 2 mg three times a week has been the general rule . A once or twice a week schedule, as used in Case 2 , does not appear to be very effective. In Case 5 , a 2-mg dose seemed to be practically ineffective , and was replaced by an increased dose of 4 mg , which proved effective.
No untoward effects have been observed except the pain at the site of injection. Various authors already reported that long-term HGH therapy is effective in pituitary dwarfism (Soyka et al., 1970) . They agree, however, that the effect is marked initially, but gradually declines somewhat. Table 3 shows their data with ours. In all reports, the patients' growth in height limited to 2 to 4 cm a year before therapy; in the first year with HGH administration they grow by about 10 cm, and subsequently they continue to grow at the rate of 6 to 9 cm a year.
Regarding the dose and frequency of injection of HGH, our experience has suggested that a once or twice a week injection schedule is inadequate. According to Soyka et al. (1970) , there is no significant difference in effect between administering 6 mg a week in daily 1-mg doses and in three 2-mg doses, but administering all 6 mg in a single weekly dose is less effective. Raben (1968) also reported that it is best to administer 2 mg intramuscularly three times a week, and that a 1-mg dose administered three times a week suffices if the patient weighs less than 40 pounds. Soyka et al.(1968) reported that, if the rate of growth with HGH decreases to less than 6 cm a year, the effectiveness of the therapy can be restored by increasing the dose to 4 mg. In our experience, the growth rate dropped below 6 cm/yr in the fourth year in Case 1, in the third year in Case 2, and after 2 1/2 years in Case 4. Therefore, increased doses will be used in Cases 1 and 4 to see how they will affect the growth rates. Such decrease of effect has been considered to be partly due to the formation of HGH antibodies. Since their presence has been demonstrated in three of our cases, it is conceivable that antibodies are responsible for the phenomenon. Soyka et al. (1970) have suggested that HGH becomes less effective with the loss of stored fat, and facilitates height growth more effectively when sufficient stored fat is present, that is, when the subject is taking sufficient calorie and gaining weight.
Two types of HGH antibody formation are considered. In the first type, antibody develops usually during the first year of therapy, and tends to inhibit the growth promoting and anabolic effects of HGH; in the second, low level of antibody appears and does not appear to seriously impair continued responsiveness. Tanner and Whitehouse (1967) reported the appearance of the first type of antibody in four out of 16 cases and Prader et al.(1967) in eight out of 18 cases, whereas Raben (1968) and Soyka et al.(1970) did not recognize the suggested that whether or not antibody formation of the first type occurs depends on the purity of HGH; the less pure it is, the more likely to produce antibody. (Soyka et al., 1970) . In our two cases in which antibodies have been discovered, increased doses of HGH will be used to see their effect on the growth rates of the patients.
The bone age/height age progress ratio is No untoward effects have been observed in our cases with the exception of pain at the injection site. In this respect we agree with other authors, who reported no particular side effects. Despite the antibody formation in some cases, no allergic reaction has been reported.
